Navigation Links
Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
Date:11/12/2008

edominantly result in antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue developme
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
2. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
3. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
4. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
6. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
7. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
8. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
9. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
(Date:2/27/2015)... SOUTH PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, ... corporate update and reported financial results for the fourth ... "2014 was a transformative year for PTC. ... on delivering and developing RNA-targeted therapies in the rare ... Officer, PTC Therapeutics, Inc. "We are proud to bring ...
(Date:2/27/2015)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today announced that it will ... March 10, 2015. Rob Kill , President and ... will present at 4:00 p.m. Pacific Time and meet ... the Ritz Carlton in Laguna Niguel, CA. ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
... to Treat Renal Artery Obstructions and Lower Blood ... Pressure in Patients Not Responding to Medication, ABBOTT ... enrollment of the first patient in HERCULES (Herculink,Elite Cobalt ... U.S. clinical trial designed to evaluate the safety and,effectiveness ...
... Pivotal Phase -, WALTHAM, Mass., Sept. 25 ... clinical trial strategy for,the SEPET(TM) Liver Assist Device including ... and Drug Administration (FDA).,In a meeting held between Arbios ... the FDA indicated that, pending receipt of a final,report, ...
Cached Medicine Technology:Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 2Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 3Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 2Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 3Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 4
(Date:2/28/2015)... Ohio (PRWEB) February 28, 2015 ... Motivational? Supportive? Strategic? , There are all kinds ... strengths. To raise awareness of the advantages and ... firm PeopleKeys is launching a new product this ... clients better understand the connection between personality type, ...
(Date:2/28/2015)... The noted Friedman Dental Group of ... officially relaunched their website. The new version of the ... a new section about their team members. Potential and ... biographies of each Friedman Dental Group team member including ... designed to provide our patients with the opportunity to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Developers of ... of a new overlay plugin for Final Cut Pro X ... , “FCPX Overlay Chromatic gives users total control over 6k ... Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic was ... easy to use interface.” , FCPX Overlay Chromatic Grunge 6K ...
(Date:2/28/2015)... Powermod ” was featured on NewsWatch as part of its ... and coolest technology products and services available to consumers. Scott ... conducted the review and shared with viewers how they provide ... a low battery and no way to charge a phone ... daily basis. Even when a person does have a charger, ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a ... new security reader named Guardian 2. The correct ... new biometric scanner that significantly increases the complexity ... new biometric scanner provides fast and easy access ... narcotics lockers with Vanguard technology tracks ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... yesterday accused the commonwealth of bankrolling public hospitals but ... spent.// ,He attacked state governments calling ... to fund public hospitals using the "river of gold" ... outraged at Mr Abbott's position accused him of short-changing ...
... reported to be healthy after undergoing the first super specialized ... ,Ritubrata Saha, 23, who had been obese since childhood, ... ,Today, Saha is grinning ear to ear. The man finally ... ,With seven percent of Indian children growing up ...
... whose blood were tested on the same day by PathWest, has ... the patient's blood// showed up HIV positive in an initial test ... did not notify the right patient about the positive test, which ... four months without knowing it. ,The mix-up was revealed ...
... dog toys distributed to children as reading incentives for the ... been recalled in libraries nationwide because they contain elevated levels ... toy registered a lead paint content of 0.277 percent against ... of the toys. ,Highsmith Inc., from ...
... (HLL), the largest condom manufacturing unit in the country, ... ,"It includes a vibrating ring plus a condom, ... for women," said HLL chairman cum managing director M. ... these products would be imported and depending on the ...
... Forest University School of Medicine were expecting a standard ... semi-conscious,// vomiting “patient” was rolled into the lecture hall ... case. ,“SimMan?,” a reproduction of an average-size ... patient makes realistic heart, lung, and bowel sounds and ...
Cached Medicine News:Health News:Health Minister Slams State Health Governments 2Health News:Computerized Patient Used to Teach Science to Medical Students 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: